Boehringer Ingelheim Plans Biopharmaceuticals Facility in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Plans Biopharmaceuticals Facility in China


Boehringer Ingelheim signed an alliance agreement and contract to build a cGMP biopharmaceuticals facility with Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) in Pudong, Shanghai, the company announced in a press release. The new site will provide a full range of development and clinical services to Chinese and multinational customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China using mammalian cell-culture technology, the company claimed.

The facility will include technical process development and cGMP manufacturing and will be ready for operation in early 2016.
 “Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high-quality biopharmaceuticals in China,” stated Christian Boehringer, chairman of the Shareholders Committee, in the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here